Listing of Mesothelioma Clinical Trials

Listing of All NCI Mesothelioma Clinical Trials
 

 

The National Cancer Institute currently lists 35 clinical trials for treatment of patients with mesothelioma.  Twenty three of these trials are in the United States.  Clinical trials are studies designed to help cancer patients. A listing of the trial titles by phase is shown below. Five of the trials are only in Europe, and 21 are in the U.S.
 
To see the most current patient statements on these trials go to the National Cancer Institute’s clinical trials search page.  Select mesothelioma from the list of cancers and then select treatment under the Type of Trial and hit search at the bottom of the page.  You can also see the health professional statements that include the detailed eligibility criteria for the trials.

 
 

Mesothelioma Clinical Trials Listing by Phase

 

Phase III (1 trial in US)

Last Modified: 2/15/2007     First Published: 12/1/1997  
 
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
 
Protocol ID numbers: ALFACELL-P30-302, NCT00003034, NCI-V97-1273
 
Trial Contact Information Trial Lead Organizations Alfacell Corporation
Diane Scudiery, Protocol chair Ph: 973-748-8082
 
 

Phase II (7 trials in US)

 
1. Phase II Randomized Study of Pemetrexed Disodium Combined With Either Gemcitabine or Carboplatin in Patients With Advanced Malignant Mesothelioma of the Pleura
 
Protocol ID numbers: ECOG-E1B03
NCT00101283, NCCTG-E1B03
 
 
2. Phase II Study of AZD2171 in Patients With Unresectable Malignant Pleural Mesothelioma
   
Protocol ID numbers: SWOG-S0509, NCT00243074
  
 
3. Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery
 
Protocol ID numbers:  UCCRC-14203B, NCT00309946, NCI-7103
 
 
4. Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
 
Protocol ID numbers: AVF3442S, NCT00295503
 
 
5. Phase II Study of Induction Combination Chemotherapy Comprising Methotrexate, Vinorelbine Ditartrate, and Cisplatin With or Without Surgery and Adjuvant Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
 
Protocol ID numbers: CASE-CCF-IRB-5179, CASE-CCF-0755, NCT00354393
 
 
6. Phase II Study of PXD101 as Second-Line Therapy in Patients With Unresectable Malignant Pleural Mesothelioma
 
Protocol ID numbers: CCC-PHII-67, NCT00365053, NCI-7255
 
 
7.  Phase II Study of Pazopanib Hydrochloride in Patients With Malignant Pleural Mesothelioma
 
Protocol ID numbers: NCCTG-N0623, NCT00459862, N0623
 
 
Phase I (13 trials in US)
 
Combination Chemotherapy in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases. 
Trial number: NCI-02-C-0205J
 
Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies. Trial number: DFCI-03082
 
FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer. Trial number: NCI-05-C-0010
 
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors. Trial number: 2005_006
 
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors.
Trial number: CA225-101
 
Gene Therapy for Pleural Malignancies. Trial number: 803776
 
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component). Trial number: CS1008-A-U101
 
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer. Trial number:  MORAb-009-001
 
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors.
Trial number: CA187-002
 
A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer.
Trial number: CA165-030
 
Monoclonal Antibody MORAb-009 in Treating Patients With Recurrent Advanced Tumors That Express Mesothelin. Trial number: NCI-06-C-0196
 
 
European Trials
 
1. Phase III Randomized Study of Active Symptom Control With Versus Without Chemotherapy in Patients With Malignant Pleural Mesothelioma
 
Protocol ID numbers: BTS-MRC-MS01
EU-20349, ISRCTN54469112, NCT00075699
 
 
2. Phase II Study of Neoadjuvant Chemotherapy Comprising Pemetrexed Disodium and Cisplatin Followed By Extrapleural Pneumonectomy and High-Dose Postoperative 3D-Conformal Radiotherapy in Patients With Malignant Pleural Mesothelioma
 
Protocol ID numbers: EORTC-08031
EudraCT-2004-004273-28, NCT00227630
 
   
 
3. Phase II Study of Bortezomib and Cisplatin as First-Line Treatment in Patients With Malignant Mesothelioma
    
Protocol ID numbers: EORTC-08052
EUDRACT-2006-000009-51, JJPRD-26866138CAN2012, NCT00458913, 08052
 
 
4. Phase II Study of Bortezomib in Patients With Malignant Pleural Mesothelioma
  
Protocol ID numbers: ICORG-05-10
EU-20748, EUDRACT-2005-004420-39, ICORG-05-10
 
 
5. Randomized Pilot Study of Neoadjuvant Combination Chemotherapy With Versus Without Surgery and Adjuvant Radiotherapy in Patients With Resectable Malignant Mesothelioma
     
Protocol ID numbers: ICR-CTSU-MARS
EU-20532, NCT00253409